, Volume 34, Issue 10, pp 695–701 | Cite as

Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats

  • M. L. McCaleb
  • M. L. McKean
  • T. C. Hohman
  • N. Laver
  • W. G. RobisonJr.


The progressive increase in urinary albumin excretion, which precedes the development of diabetic nephropathy, can be prevented in diabetic rats if the aldose reductase inhibitor, tolrestat, is administered at the initiation and throughout the duration of hyperglycaemia. We therefore determined the ability of tolrestat to intervene in the further progression of already established urinary albumin excretion of streptozotocin-diabetic female Wistar rats. Two months after streptozotocin injection, diabetic rats were grouped as low-urinary albumin excretion (0.2–1.0 mg albumin/day) or high-urinary albumin excretion (1.9–5.9 mg albumin/day), at which time tolrestat intervention (25 mg/kg per day) was begun for half of the diabetic rats in each urinary albumin excretion group. After six months of treatment tolrestat caused a significant reduction in the urinary albumin excretion rate of the low-urinary albumin excretion group only. The diabetes-induced rise of total urinary protein in both groups was significantly reduced by tolrestat. Furthermore, the diabetes-induced increase (49%) in the thickness of the basement membranes of retinal capillaries from the outer plexiform layer was significantly diminished by tolrestat administration. In conclusion, intervention therapy with the aldose reductase inhibitor, tolrestat, can reduce the progression of urinary albumin excretion and retinal basement membrane thickening in long-term diabetic rats.

Key words

Nephropathy retinopathy diabetic complications aldose reductase 


  1. 1.
    Viberti GC, Walker JD (1988) Diabetic nephropathy: etiology and prevention. Diab Metab Rev 4: 147–162Google Scholar
  2. 2.
    Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Eng J Med 311: 89–93Google Scholar
  3. 3.
    Mauer SM, Brown DM, Matas AJ, Steffes MW (1978) Effects of pancreatic islet transplantation on the increased urinary excretion rates in intact and uninephrectomized rats with diabetes mellitus. Diabetes 27: 959–964PubMedGoogle Scholar
  4. 4.
    Rasch R, Mogensen CE (1980) Urinary excretion of albumin and total protein in normal and streptozotocin diabetic rats. Acta Endocrinol 95: 376–381PubMedGoogle Scholar
  5. 5.
    McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D (1988) Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabetic Comp 2: 16–18CrossRefGoogle Scholar
  6. 6.
    Report of the National Commission on Diabetes to the Congress of the United States (1976) Vol. 1, The long-range plan to combat diabetes. Bethesda, MD: Department of Health, Education, and Welfare (DHEW publication no. (NIH) 76-1018)Google Scholar
  7. 7.
    Ashton N (1974) Vascular basement membrane changes in diabetic retinopathy. Br J Ophthalmol 58: 344–366PubMedGoogle Scholar
  8. 8.
    Bloodworth Jr JMB, Engerman RL, Camerini-Davalos RA, Powers KL (1970) Variations in capillary basement membrane width produced by aging and diabetes mellitus. Adv Metab Disord 1 [Suppl]: 279–295PubMedGoogle Scholar
  9. 9.
    Williamson JR, Kilo C (1977) Current status of capillary basement-membrane disease in diabetes mellitus. Diabetes 26: 65–73PubMedGoogle Scholar
  10. 10.
    Nagata M, Katz ML, Robison Jr WG (1986) Age-related thickening of retinal capillary basement membranes. Invest Ophthalmol Vis Sci 27: 437–440PubMedGoogle Scholar
  11. 11.
    Robison Jr WG (1988) Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors. In: Camerini-Davalos RA, Cole HS (eds) Prediabetes, advances in experimental medicine and biology, Vol 246. Plenum Publishing, New York, pp 365–372Google Scholar
  12. 12.
    Robison Jr WG, Kador PF, Kinoshita JH (1983) Retinal capillaries: Basement membrane thickening by galactosemia prevented with an aldose reductase inhibitor. Science 221: 1177–1179PubMedGoogle Scholar
  13. 13.
    Frank RN, Keirn RJ, Kennedy A, Frank KW (1983) Galactose-induced retinal capillary basement membrane thickening: prevention by sorbinil. Invest Ophthalmol Vis Sci 24: 1519–1524PubMedGoogle Scholar
  14. 14.
    Chakrabarti S, Sima AAF (1989) Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. Diabetes 38: 1181–1186PubMedGoogle Scholar
  15. 15.
    Kroc Collaborative Study Group (1984) Blood glucose control and the evaluation of diabetic retinopathy and albuminuria. N Eng J Med 311: 365–372Google Scholar
  16. 16.
    Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandrik L, Aagenaes O (1988) Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus, The Oslo Study. Acta Endocrinol 117: 19–25PubMedGoogle Scholar
  17. 17.
    Cohen AJ, McGill PD, Rossetti RG, Gugerski DL, Like AA (1987) Glomerulopathy in spontaneously diabetic rat. Impact of glycemic control. Diabetes 36: 944–951PubMedGoogle Scholar
  18. 18.
    Robison Jr WG, Kador PF, Akagi Y, Kinoshita JH, Gonzalez R, Dvornik D (1986) Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes 35: 295–299PubMedGoogle Scholar
  19. 19.
    Guerrant GO, Moss CW (1984) Determination of monosaccharides as aldonitrile, o-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem 56: 633–638Google Scholar
  20. 20.
    Beyer-Mears A, Cruz E, Edelist T, Varagiannis E (1986) Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor. Pharmacol 32: 52–60PubMedGoogle Scholar
  21. 21.
    Kawazu S, Watanabe T, Hokama A et al. (1987) Diabetic nephropathy and sorbitol pathway in BB/W rat. In: Sakamoto N, Alberti KGMM, Hotta N (eds) Recent trends in management of diabetes mellitus. Elsevier, Amsterdam, pp 595–597Google Scholar
  22. 22.
    Tilton RG, Chang K, Pugliese G et al. (1989) Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38: 1258–1270PubMedGoogle Scholar
  23. 23.
    Daniels BS, Hostetter TH (1989) Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 38: 981–986PubMedGoogle Scholar
  24. 24.
    Mauer SM, Steffes MW, Azar S, Brown DM (1989) Effects of sorbinil on glomerular structure and function in long-termdiabetic rats. Diabetes 38: 839–846PubMedGoogle Scholar
  25. 25.
    Stribling D, Armstrong FM, Harrison HE (1989) Aldose reductase in the etiology of diabetic complications: 2. Nephropathy. J Diab Comp 3: 70–76CrossRefGoogle Scholar
  26. 26.
    Mogensen CE (1987) Early diabetic renal involvement and nephropathy. In: Alberti KGMM, Krall LP (eds) The diabetes annual, 13. Elsevier, Amsterdam, pp 306–324Google Scholar
  27. 27.
    Goldfarb S, Ziyadeh FN (1989) Glomerular lesions and microalbuminuria in diabetes. N Engl J Med 321: 759PubMedGoogle Scholar
  28. 28.
    Goldstein RS, Tarloff JB, Hook JB (1988) Age-related nephropathy in laboratory rats. FASEB J 2: 2241–2251PubMedGoogle Scholar
  29. 29.
    McCaleb ML, Sredy J (1989) Metabolic abnormalities of the hyperglycemic obese Zucker rat. J Cell Biochem [Suppl. 13E]: 238Google Scholar
  30. 30.
    Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kid Int 33: 667–672Google Scholar
  31. 31.
    Niskanen L, Uusitupa M, Sarlund H et al. (1990) Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33: 237–243PubMedGoogle Scholar
  32. 32.
    Granger DN, Korthuis RJ, Kvietys PR, Tso P (1988) Intestinal microvascular fluid exchange during lipid absorption. FASEB J 2: A741Google Scholar
  33. 33.
    Fischer F, Gaertner J (1983) Morphometic analysis of basal laminae in rats with long-term streptozotocin diabetes. II. Retinal capillaries. Exp Eye Res 37: 55–64CrossRefPubMedGoogle Scholar
  34. 34.
    Waber S, Meister V, Rossi GL, Mordasini R-C, Riesen WF (1981) Studies on retinal microangiopathy and coronary microangiopathy in rats with streptozotocin-induced diabetes. Virch Arch [Cell Pathol] 37: 1–10Google Scholar
  35. 35.
    Kojima K, Matsubara H, Harada T et al. (1985) Effects of aldose reductase inhibitor on retinal microangiopathy in streptozocin-diabetic rats. Jpn J Ophthalmol 29: 99–109PubMedGoogle Scholar
  36. 36.
    Chandler ML, Shannon WA, DeSantis L (1984) Prevention of retinal capillary basement membrane thickening in diabetic rats by aldose reductase inhibitors. Invest Ophthamol Vis Sci 25 [Suppl.]: 159Google Scholar
  37. 37.
    Kinoshita JH, Nishimura C (1988) The involvement of aldose reductase in diabetic complications. Diab Metab Rev 4: 323–337Google Scholar
  38. 38.
    Kinoshita JH, Datiles MB, Kador PF, Robison Jr WG (1990) Aldose reductase and diabetic eye complications. In: Rifkin H, Porte Jr D (eds) Ellenberg and Rifkin's diabetes mellitus, theory and practice, 4th edn. Elsevier, New York, pp 264–278Google Scholar
  39. 39.
    Kador PF, Akagi Y, Takahaski Y, Ikebe H, Wyman M, Kinoshita JH (1990) Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 108: 1301–1309PubMedGoogle Scholar
  40. 40.
    Robison Jr WG, Nagata M, Laver N, Hohman TC, Kinoshita JH (1989) Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 30: 2285–2292PubMedGoogle Scholar
  41. 41.
    Boulton AJM, Levin S, Comstock J (1990) A multicentre trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33: 431–437PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • M. L. McCaleb
    • 1
  • M. L. McKean
    • 1
  • T. C. Hohman
    • 1
  • N. Laver
    • 2
  • W. G. RobisonJr.
    • 2
  1. 1.Wyeth-Ayerst ResearchPrincetonUSA
  2. 2.The National Eye InstituteNational Institute of HealthBethesdaUSA

Personalised recommendations